R&D Trends

Riptide Bioscience, National Cancer Institute partner

Thursday, October 6, 2016

Henry Lopez, executive vice president of Riptide Bioscience, has announced the execution of a Cooperative Research and Development Agreement (NCI CRADA #03045) with the National Cancer Institute (NCI), part of the NIH.  The agreement carries a three-year term and is entitled, Evaluation of Riptide Bioscience’s Proprietary Peptide RP-182 in Preclinical Studies for the Treatment of Pancreatic Cancer.  Research under the CRADA is intended to generate data to support an Investigational New Drug filing of this agent with the FDA.

[Read More]

Nuevolution, Amgen collaborate in oncology and neuroscience

Tuesday, October 4, 2016

Amgen and Nuevolution have entered into a multiple target research collaboration to develop and commercialize novel therapeutics in the areas of oncology and neuroscience. Nuevolution will apply its Chemetics drug discovery platform to discover and advance potential therapeutics of interest to Amgen. The research collaboration brings together Nuevolution’s proprietary drug discovery platform with Amgen’s disease expertise and drug development capabilities.

[Read More]

NCI collaborates with Multiple Myeloma Research Foundation

Friday, September 30, 2016

The National Cancer Institute (NCI) has announced a collaboration with the Multiple Myeloma Research Foundation (MMRF) to incorporate MMRF’s wealth of genomic and clinical data about the disease into the NCI Genomic Data Commons (GDC), a publicly available database that promotes the sharing of genomic and clinical data among researchers and facilitates precision medicine in oncology. The MMRF, located in Norwalk, Connecticut, is the first non-profit to donate information to the GDC, which will include data on more than 30,000 patients who have many other types of cancers by the end of the year. NCI is part of the NIH.

[Read More]

Barda grants $43.2 million to Sanofi Pasteur for Zika

Thursday, September 29, 2016

Sanofi and its vaccines global business unit Sanofi Pasteur have announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services has agreed to a proposal to fund the manufacture of an inactivated Zika vaccine for phase II development. Sanofi Pasteur committed to researching and developing a vaccine to prevent Zika in February, shortly after the World Health Organization declared an emergency.

[Read More]